Program
GIA632
A development code.
In Novartis's pipeline, IL-15 mAb
. Its studies are mostly in Vitiligo · Lichen Planus · Dermatitis, Atopic, led by Novartis.
Furthest: phase 2, since Oct 22, 20253 company-led studies, 3 open or runningNext primary completion: May 17, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 33 open or running | phase 2since Oct 22, 2025 | Oct 22, 2025 | May 17, 2027phase 2 · NCT07220577 |
- Named in Novartis’s own pipeline as
GIA632
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 22, 2025First study: phase 2 study in Dermatitis, AtopicFirst studyNCT07220577 · 34 enrolled · United States, Bulgaria, Canada and more
- Feb 18, 2026Phase 2 study in VitiligoNCT07431177 · 210 planned · United States, Argentina, Australia and more
- Aug 17, 2026Phase 2 study in Lichen PlanusNCT07775924 · 259 planned · United States, Australia, Canada and more
Ahead
- May 17, 2027Primary completion: phase 2 study in Dermatitis, AtopicNCT07220577
- Jun 6, 2028Primary completion: phase 2 study in VitiligoNCT07431177
- Nov 22, 2028Primary completion: phase 2 study in Lichen PlanusNCT07775924
TargetBeta
“IL-15 mAb”the company's pipeline, read by Claude · source
Other programs on IL15
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| nogapendekin alfa inbakiceptrule | ImmunityBio | phase 3 | 45 |
| efserakefusp alfa | Jiangsu HengRui Medicine | phase 3 | 6 |
| belacabnagene franleucelrule | nkarta-inc | phase 2 | 3 |
| SPGL008rule | 3SBio | phase 2 | 3 |
| Daxokafusp Alfa | Sanofi | phase 2 | 2 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07775924Lichen Planus · United States, Australia, Canada and more | 2 | Recruiting | Nov 22, 2028 | 259 |
| NCT07431177Vitiligo · United States, Argentina, Australia and more | 2 | Recruiting | Jun 6, 2028 | 210 |
| NCT07220577Dermatitis, Atopic · United States, Bulgaria, Canada and more | 2 | Active, not recruiting | May 17, 2027 | 34 |
How it is read
Names in the registry
- “GIA632”, 3 entries
Codes read as this program: GIA632.
Conditions, from the studies’ own filings
- Vitiligo, 1 study
- Lichen Planus, 1 study
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.